Fisher Scientific International said this week that president and CEO David Della Penta will retire at the end of 2006. He will continue to be responsible for all of the company's operating activities until that time, Fisher said. Della Penta joined Fisher in April 1998.
Genetix Group said this week that it will appoint Andrew Kellet as finance director, effective March 27. Kellet will replace Gary Corsi, who will leave the company at the end of this month, Genetix said.
Kellet is currently employed by Quest Diagnostics, where he has been since 2000. He serves as Quest's finance director for Europe and global controller for clinical trials and pharmaceutical business development. He has also held senior financial positions with MDC Corporation, General Cable, and United Biscuits.
Millipore this week announced the appointment of Bruce Bonnevier as corporate vice president of global human resources, and Roland Heinrich as vice president of R&D for the bioprocess division.
Bonnevier previously was vice president of human resources for Hillenbrand Industries, and has served in a similar capacity at Shipley Company, now the electronic materials division of Rohm and Hass. He holds a PhD from the Fielding Institute, an MS from the University of Pennsylvania, and an MA and BA from Pennsylvania State University.
Heinrich most recently was employed as vice president of strategic operations planning for the biopharma and vaccines division of Wyeth. Prior to that, he was a director of manufacturing for protein purification and plant manager at Bayer Corporation. He earned his postdoc at Cambridge University, and a PhD from the University of Arizona.
Gerard Willis has joined MultiCell Technologies as CFO, MultiCell said this week.
Willis has most recently served as CFO for Immusol. He has also served as vice president of finance and CFO for Nanogen, Trega Biosciences, and Molecular Biosystems. He holds a BA in business administration from the University of Notre Dame.
Eric Neumann joined Teranode as senior director of product strategy, the company said earlier this week.
With 20 years of experience in bioinformatics and semantic technologies development, Neumann has held executive positions with Sanofi-Aventis Pharmaceuticals; Beyond Genomics; NetGenics; and Bolt, Beranek, and Newman.
Ian Campbell joined Akubio as the business development director, the company announced earlier this week.
Until recently, Campbell was a business development consultant of The Automation Partnership. Prior to this, he spent three years in business development at Corning Microarray Technology and two years in commercial roles within Biacore AB manufacturers. He holds a PhD in biochemistry and molecular biology.
Molecular Devices this week launched SoftMax Pro 5 data acquisition and analysis software for its line of microplate readers. The new software is available in two editions: SoftMax Pro 5 for use in research and academic laboratories, and SoftMax Pro 5 GxP with FDA 21 CFR Part 11 compliance for the pharmaceutical and biotech industries. Both software versions are compatible with Mac OS X and Microsoft Windows.
The software introduces 5-parameter logistic curve fit and parallel line analysis graphing functions to allow users to compare and QC their sample standards, MDCC said. Users can select from 120 pre-developed assay protocols, including for IC-50 determination, enzymology, early ADME, nucleic acids, and ELISA.
Genedata this week released of Genedata Screener 4.0, an open and scalable software platform for high-throughput screening analysis.
The software includes a public application programming interface and advanced procedures for analyzing high-content screening data (see CBA News, 9/19/2005). New features include an API to link Screener's database resources with the client's existing corporate information portals, and new sorting and filtering capabilities that are specially designed for lead discovery and compound validation, Genedata said.